Sanyou and KangaBio team up to advance antibody drug development

Sanyou Biopharmaceuticals and Shanghai KangaBio have sign a licensing agreement to accelerate the development and innovation of the first monoclonal antibody drug.

The latest agreement will grant KangaBio an exclusive license to use the antibody to carry out research, development, production and commercialization of immunotherapy products.

Sanyou and KangaBio will join forces to propose the development of new prodrugs for immunotherapy based on their expertise and industry resources.

Shanghai KangaBio Founder and CEO Dr. Weidong Jiang said, “KangaBio is committed to developing low toxicity, high efficacy immuno-agonists and innovative multi-specific antibody prodrugs.

“This strategic partnership with Sanyou is expected to utilize the advantages of international leader Sanyou’s innovative antibody drug development and transformation platform to further enrich KangaBio’s innovative product portfolio, accelerate the R&D of our innovative antibody drugs and meet unmet clinical needs.

The companies previously signed a partnership agreement for two monoclonal antibodies from Sanyou and also entered into a high-level term sheet.

Besides transferring the license of drug candidates, the companies have reached joint development, commissioned research and development (R&D), technical work as well as other types of R&D partnerships in stages.

To provide full support for KangaBio’s drug development, Sanyou makes full use of its six kinds of one-stop antibody drug innovative integrated services.

In addition, 11 types of flexible and adaptable antibody drug R&D technical services and 11 types of various antibody generation services of the company will be utilized.

Founder and CEO of Sanyou Biopharmaceuticals, Dr. Guojun Lang, said, “During the many past collaborations, Sanyou has saved valuable time with preclinical R&D of drugs for KangaBio, thanks to the comprehensive innovative drug development system and rich industrialization experiences.

“We look forward to further communication and collaboration with KangaBio in the future and hope that this collaboration will bring benefits to KangaBio’s development.”

Related companies

Comments are closed.